ArticleResearch square2023

CXCL9 recombinant adeno-associated virus (AAV) virotherapy sensitizes glioblastoma (GBM) to anti-PD-1 immune checkpoint blockade.

Christina von Roemeling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.